Scoliosis Market Size, Share, Competitive Landscape, and Trend Analysis Report by Type, Age Group, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033

The scoliosis market was valued at $537.78 million in 2023 and is estimated to reach $803.67 million by 2033 exhibiting a CAGR of 4.1% from 2024 to 2033

Market Introduction and Definition

Scoliosis is a medical condition characterized by an abnormal lateral curvature of the spine. Typically, the spine has natural curves when viewed from the side, but it should appear straight when viewed from the front or back. In individuals with scoliosis, the spine curves to the side, forming an ‘S’ or ‘C’ shape rather than a straight line. This curvature can occur in different parts of the spine: the thoracic (upper back), lumbar (lower back), or both.

The severity of scoliosis can vary greatly. Mild cases may cause no noticeable symptoms and require minimal treatment, while severe cases can lead to significant deformities and complications such as pain, respiratory issues, and decreased mobility. Scoliosis can develop at any age, but it most commonly appears during the growth spurt just before puberty.

Key Takeaways

• The scoliosis market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• In June 2023, ImageBiopsy Lab announced it had received clearance from the U.S. Food and Drug Administration (FDA) for IB Lab LAMA, the first fully-automated radiological image processing software for geometric length and angle measurements of the lower limb on full leg X-rays. The company previously had FDA-approved its IB Lab KOALA Knee-Osteoarthritis Labeling Assistant, and intends to expand to the U.S. with additional MSK-focused software solutions.
• In January 2020, at CES 2020, Convexity Scientific Incorporated (Convexity), provider of consumer-focused respiratory medical technology, announced its purchase of the digital health assets of Wellinks Incorporated (Wellinks). With this transaction, Convexity acquires a portfolio of products and intellectual property, including software to support connected medical devices and remote patient monitoring.

Key Market Dynamics

The increasing prevalence of scoliosis, particularly among adolescents, is a significant factor driving the growth of the scoliosis market. Idiopathic scoliosis, which is the most common form, affects approximately 2-3% of adolescents globally. This equates to millions of young people being diagnosed with the condition each year. According to the Scoliosis Research Society, about 6-9 million people in the U.S. alone are affected by scoliosis, with an estimated 600,000 patient visits to private practice clinics per year and about 30,000 children being fitted with a brace annually. Moreover, the prevalence of scoliosis tends to increase with age. While adolescent idiopathic scoliosis is the most common, degenerative scoliosis becomes more prevalent among older adults, particularly due to age-related spinal degeneration. It is estimated that about 68% of people over the age of 60 have some degree of scoliosis.

Awareness about scoliosis and its symptoms is often less among the general public, particularly in developing countries with fewer healthcare resources. The World Health Organization (WHO) estimates that over 80% of scoliosis cases occur in low- and middle-income countries, where access to screening and specialized care is often lacking. Studies indicate that only about 30% of cases are diagnosed during early adolescence, while the remaining 70% go undetected or are misdiagnosed until later stages. These factors are anticipated to restrain the scoliosis market growth during the forecast period.

Non-invasive and cost-effective screening tools could make scoliosis screening more accessible, particularly in regions or communities where resources are limited. This can help in reaching a larger population and identifying cases that might otherwise have gone undetected. Increasing investments in the development of such tools stimulates innovation in medical technology, driving advancements not only in scoliosis detection but potentially in other areas of healthcare as well. These factors are anticipated to create opportunities in the scoliosis market during the forecast years.

Patent Analysis in the Global Scoliosis Market

On June 15, 2023, in the U.S., the Institute for Spine & Scoliosis, introduced the method for improved spinal correction surgery implementing non-fusion anterior scoliosis correction techniques with double screws and cords. Scoliosis correction surgery has evolved significantly over the years, with advancements focusing on minimizing invasiveness, preserving motion, and achieving better outcomes. Non-fusion anterior scoliosis correction techniques have gained popularity due to their potential advantages over traditional fusion surgeries, such as maintaining spinal flexibility and reducing the risk of adjacent segment degeneration.

Market Segmentation

The scoliosis market is segmented into type, age group, and region. On the basis of type, the market is divided into cast braces, rigid braces, and non-rigid dynamic braces. On the basis of age group, the market is divided into children, teenager, and adult. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

In North America, the scoliosis market is expanding due to several key factors. The rising incidence of scoliosis, especially among teenagers, is boosting the demand for diagnostic and treatment solutions. According to the American Association of Neurology, scoliosis affects about 2-3% of the population, which leads to roughly six to nine million people in the U.S. In addition, approximately 29,000 scoliosis surgeries are performed on adolescents in the U.S. each year. Scoliosis represents 20% of all spine deformity cases in the U.S. and accounts for 1.2% of the country's total hospital expenditures annually.

On December 19, 2023, Dr. Zeke Harkleroad, an esteemed expert in spinal health and wellness, unveiled a groundbreaking technology that has been changing the lives of scoliosis patients. Marking their 25th anniversary in the Austin community, Bee Caves Scoliosis and Chiropractic stands as a symbol of hope for many dealing with various back pain issues and scoliosis. Motivated by a dedication to innovation and patient care, Dr. Zeke's pioneering treatments are highlighted on his website and praised in outstanding online reviews.

Competitive Landscape

The major players operating in the scoliosis market include Boston Orthotics & Prosthetics, Chaneco, Spinal Technology Inc., Optec USA Inc, DJO LLC (Subsidiary of Colfax Corporation), Ossur Corporate, TRULIFE, Aspen Medical, LA Brace Center, Beacon Prosthetics & Orthotics, and others.

Recent Key Strategies and Developments

• On February 15, 2022, Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced that the European Commission had granted marketing approval for NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone. This once-weekly injection is designed to treat children and adolescents aged 3 and above who have growth disturbance due to insufficient secretion of growth hormone. NGENLA offers a new treatment option for growth hormone deficiency (GHD) that decreases the frequency of necessary injections from once daily to once weekly, benefitting pediatric patients, caregivers, and healthcare providers.
• In December 2021, a National Scoliosis Centre article reported that Johns Hopkins University's Department of Pediatric Orthopedics was conducting clinical trials utilizing Dysport as an innovative treatment for scoliosis in children. Dysport is employed to relax specific back muscles surrounding the scoliosis curve, thereby enhancing spine flexibility. The treatment involves two doses administered four months apart.

Key Sources Referred

1. Centers for Disease Control and Prevention (CDC)
2. National Institutes of Health (NIH)
3. National Institute of Child Health and Human Development (NICHD)
4. World Health Organization (WHO)
5. Scoliosis Research Society (SRS)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the scoliosis market segments, current trends, estimations, and dynamics of the scoliosis market analysis from 2023 to 2033 to identify the prevailing scoliosis market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the scoliosis market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global scoliosis market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the points mentioned above, the report includes the analysis of the regional as well as global point of care testing trends, key players, market segments, application areas, and market growth strategies.